Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial
Abstract Background The effectiveness of alteplase for ischemic stroke treatment is limited, partly due to the occurrence of intracranial and extracranial hemorrhage. Mutant pro-urokinase (m-proUK) does not deplete fibrinogen and lyses fibrin only after induction with alteplase. Therefore, this trea...
Main Authors: | Nadinda A. M. van der Ende, Bob Roozenbeek, Lucas E. M. Smagge, Sven P. R. Luijten, Leo A. M. Aerden, Petra Kraayeveld, Ido R. van den Wijngaard, Geert J. Lycklama à Nijeholt, Heleen M. den Hertog, H. Zwenneke Flach, Alexis C. Wallace, Victor Gurewich, Gregory J. del Zoppo, William J. Meurer, Hester F. Lingsma, Aad van der Lugt, Diederik W. J. Dippel, on behalf of the DUMAS Investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-08-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-022-06596-z |
Similar Items
-
Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke
by: Ángel Estella, et al.
Published: (2022-09-01) -
Different Strategies and Our Approach for Treatment of Mitral Valve Thrombosis; Treatment with Alteplase
by: Ata Niyazi Ecevit, et al.
Published: (2018-07-01) -
Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
by: Mingfeng Zhai, et al.
Published: (2023-05-01) -
Intravenous thrombolysis in acute ischemic stroke: A prospective cross-sectional observational study in Kashmir
by: Javed Khan, et al.
Published: (2022-01-01) -
Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis – A retrospective cohort analysis
by: Vilhelm Sjögren, et al.
Published: (2023-06-01)